A molecular star in the wars against cancer - PubMed

• PMID: 12181399
• DOI: 10.1056/NEJMp020079

Comment

A molecular star in the wars against cancer

Robert Schwartz. N Engl J Med. 2002.

Comment on

• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Clinical Trial.

Similar articles

• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Apperley JF, et al. N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150. N Engl J Med. 2002. PMID: 12181402

• Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.

  Cornfield D, Shah U, Cross N, Bennett C, Sun G. Cornfield D, et al. J Clin Oncol. 2012 Mar 20;30(9):e109-11. doi: 10.1200/JCO.2011.39.0377. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331939 No abstract available.

• Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.

  Tipirneni E, Buttar A, Brettler D, Miron P, Bathini V. Tipirneni E, et al. Ann Hematol. 2012 Apr;91(4):637-8. doi: 10.1007/s00277-011-1296-y. Epub 2011 Jul 22. Ann Hematol. 2012. PMID: 21833478 No abstract available.

• Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.

  Cross NC, Reiter A. Cross NC, et al. Acta Haematol. 2008;119(4):199-206. doi: 10.1159/000140631. Epub 2008 Jun 20. Acta Haematol. 2008. PMID: 18566537 Review.

• Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.

  Cortes J, Kantarjian H. Cortes J, et al. Cancer. 2004 May 15;100(10):2064-78. doi: 10.1002/cncr.20211. Cancer. 2004. PMID: 15139047 Review.

Cited by

• Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

  Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y. Nissen LJ, et al. J Clin Invest. 2007 Oct;117(10):2766-77. doi: 10.1172/JCI32479. J Clin Invest. 2007. PMID: 17909625 Free PMC article.

• Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.

  Li-Wan-Po A, Farndon P, Craddock C, Griffiths M. Li-Wan-Po A, et al. Eur J Clin Pharmacol. 2010 Apr;66(4):369-74. doi: 10.1007/s00228-009-0779-4. Epub 2010 Jan 29. Eur J Clin Pharmacol. 2010. PMID: 20111860

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.